John M Moriarty1, Ramsey Al-Hakim1, Anshuman Bansal1, Jonathan K Park2. 1. Division of Interventional Radiology, Department of Radiology, University of California, Los Angeles, 757 Westwood Pl., Los Angeles, CA 90095. 2. Division of Interventional Radiology, Department of Radiology, University of California, Los Angeles, 757 Westwood Pl., Los Angeles, CA 90095; Division of Interventional Radiology, Department of Radiology, West Los Angeles VA Medical Center, Los Angeles, California. Electronic address: jonathan.park09@gmail.com.
Abstract
PURPOSE: To describe initial single-center experience with a thrombectomy device in managing right atrial and caval thrombi, tumors, and vegetations. MATERIALS AND METHODS: A retrospective analysis of AngioVac thrombectomy performed in 16 patients (mean age 53 y ± 13; 8 men, 8 women) between August 2013 and August 2015 was performed. Indications included right atrial mass/thrombus (6/16; 37.5%) and iliocaval thrombus (10/16; 62.5%). Procedural success was defined as aspiration of > 70% volume of atrial mass/thrombus or restoration of antegrade caval flow. RESULTS: Procedural success was achieved in 4/6 (67%) right atrial masses/thrombi and 10/10 (100%) caval thrombi. All patients (8/8; 100%) with caval thrombus presenting with swelling/edema had improvement or resolution of symptoms. There were no procedural or periprocedural mortalities; complications included one major (6.3%; intraprocedural pulmonary embolus) and one minor (6.3%; access site hematoma not requiring transfusion) complication. Of 16 patients, 14 (87.5%) survived to discharge at a mean of 10 days ± 8 (range, 1-23 d), and 12 patients (75%) were alive at last known follow-up at a mean of 385 days ± 267 (range, 63-730 d). At a mean of 194 days ± 177 (range, 41-372 d), 4/16 (25%) patients were dead; no death was related to AngioVac thrombectomy. At a mean of 66 days ± 21 (range, 49-90 d) after intervention, 3/14 (21.4%) cases with procedural success had local recurrence of mass/thrombus. CONCLUSIONS: AngioVac thrombectomy can be performed with high procedural success with clinical benefit in patients with right atrial and caval masses/thrombi. Published by Elsevier Inc.
PURPOSE: To describe initial single-center experience with a thrombectomy device in managing right atrial and caval thrombi, tumors, and vegetations. MATERIALS AND METHODS: A retrospective analysis of AngioVac thrombectomy performed in 16 patients (mean age 53 y ± 13; 8 men, 8 women) between August 2013 and August 2015 was performed. Indications included right atrial mass/thrombus (6/16; 37.5%) and iliocaval thrombus (10/16; 62.5%). Procedural success was defined as aspiration of > 70% volume of atrial mass/thrombus or restoration of antegrade caval flow. RESULTS: Procedural success was achieved in 4/6 (67%) right atrial masses/thrombi and 10/10 (100%) caval thrombi. All patients (8/8; 100%) with caval thrombus presenting with swelling/edema had improvement or resolution of symptoms. There were no procedural or periprocedural mortalities; complications included one major (6.3%; intraprocedural pulmonary embolus) and one minor (6.3%; access site hematoma not requiring transfusion) complication. Of 16 patients, 14 (87.5%) survived to discharge at a mean of 10 days ± 8 (range, 1-23 d), and 12 patients (75%) were alive at last known follow-up at a mean of 385 days ± 267 (range, 63-730 d). At a mean of 194 days ± 177 (range, 41-372 d), 4/16 (25%) patients were dead; no death was related to AngioVac thrombectomy. At a mean of 66 days ± 21 (range, 49-90 d) after intervention, 3/14 (21.4%) cases with procedural success had local recurrence of mass/thrombus. CONCLUSIONS: AngioVac thrombectomy can be performed with high procedural success with clinical benefit in patients with right atrial and caval masses/thrombi. Published by Elsevier Inc.
Authors: Cara M Michelson; Cornelius M Dyke; Douglas J Wick; Rory Guenther; Dylan Dangerfield; Matthew E Wiisanen Journal: J Extra Corpor Technol Date: 2017-12
Authors: Maureen P Kohi; Ryan Kohlbrenner; Kanti P Kolli; Evan Lehrman; Andrew G Taylor; Nicholas Fidelman Journal: Cardiovasc Diagn Ther Date: 2016-12
Authors: Connor Tice; Matthew Seigerman; Paul Fiorilli; Steven C Pugliese; Sameer Khandhar; Jay Giri; Taisei Kobayashi Journal: Curr Cardiovasc Risk Rep Date: 2020-10-06